(Q38137208)

29 August 2017

0 references

Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis (English)

1 reference

29 August 2017

1 reference

1 reference

Tea Reljic

3

0 references

Benjamin Djulbegovic

8

object named as

Benjamin Djulbegovic

1 reference

29 August 2017

author name string

Mohamed A Kharfan-Dabaja

1

1 reference

29 August 2017

Mehdi Hamadani

2

1 reference

29 August 2017

Rachel Pyngolil

4

1 reference

29 August 2017

Rami S Komrokji

5

1 reference

29 August 2017

Jeffrey E Lancet

6

1 reference

29 August 2017

Hugo F Fernandez

7

1 reference

29 August 2017

Ambuj Kumar

9

1 reference

29 August 2017

language of work or name

English

0 references

publication date

23 August 2013

1 reference

British Journal of Haematology

29 August 2017

published in

1 reference

29 August 2017

volume

163

1 reference

29 August 2017

issue

3

1 reference

29 August 2017

page(s)

315-325

1 reference

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

29 August 2017

cites work

1 reference

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

21 January 2018

1 reference

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

21 January 2018

1 reference

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

21 January 2018

1 reference

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

21 January 2018

1 reference

Anthracycline dose intensification in acute myeloid leukemia

21 January 2018

1 reference

Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey.

21 January 2018

1 reference

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

21 January 2018

1 reference

High-dose daunorubicin in older patients with acute myeloid leukemia

21 January 2018

1 reference

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

21 January 2018

1 reference

Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy

21 January 2018

1 reference

Gemtuzumab ozogamicin: time to resurrect?

21 January 2018

1 reference

Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug

21 January 2018

1 reference

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

21 January 2018

1 reference

Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

21 January 2018

1 reference

Effect Measures for Meta-Analysis of Trials with Binary Outcomes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.12528

1 reference

29 August 2017

1 reference